(4) The sale, purchase, or trade of a drug or an offer to sell, purchase, or trade a drug among hospitals or other health care entities that are under common control;

(5) The sale, purchase, or trade of a drug or an offer to sell, purchase, or trade a drug for emergency medical reasons;

(6) The sale, purchase, or trade of a drug, an offer to sell, purchase, or trade a drug, or the dispensing of a drug under a prescription executed in accordance with section 503(b) of the act;

(7) The distribution of drug samples by manufacturers’ and authorized distributors’ representatives;

(8) The sale, purchase, or trade of blood or blood components intended for transfusion;

(9) Drug returns, when conducted by a hospital, health care entity, or charitable institution in accordance with §203.23; or

(10) The sale of minimal quantities of drugs by retail pharmacies to licensed practitioners for office use.

§203.22 Exclusions.

Section 203.20 does not apply to:

(a) Applications for reimportation to provide emergency medical care.

(b) Applications for reimportation to provide emergency medical care shall be submitted to the director of the FDA District Office in the district where reimportation is sought (addresses found in part 5, subpart M of this chapter).

§203.11 Applications for reimportation to provide emergency medical care.

An appeal from an adverse decision by the district office involving prescription human biological products may be made to the Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 or the Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002.

§203.12 An appeal from an adverse decision by the district office.

An appeal from an adverse decision by the district office involving prescription human biological products may be made to the Center for Biologics Evaluation and Research, Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852 or the Office of Compliance, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Silver Spring, MD 20993–0002, depending on the Center responsible for regulating the product.